CGT · 혈액암 (AML/ALL) · CD20

11개 · ADC 882 · Antibody 4071 · CGT 2714 · 자동 수집 갱신 권장 · 9월 2일

PopularRecently updatedCuratedMost trialsNeeds refreshORRLatestPhase 3FDA approved11 programs

데이터 갱신 주기입니다. 갱신 대기 7,666개 보기 · Curated Core는 주간 자동 동기화됩니다.

CGTLimited DatastaleChinese PLA General HospitalPhase 2

anti-CD20-CAR vector-transduced autologous T cells (anti-CD20-CAR vector-transduced autologous T cells)

Hematopoietic/Lymphoid Cancer; Adult Acute Lymphoblastic Leukemia in Remission · CD20

#CD20#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 5Status Active
CGTLimited DatastaleOhio State University Comprehen…Phase 1

Autologous Anti-CD19/CD20/CD22 CAR T-cells (Autologous Anti-CD19/CD20/CD22 CAR T-cells)

Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive; Recurrent Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+5
Trials 2Status Recruiting
CGTLimited DatastaleChina Immunotech Pharmaceutical…Phase 1

CD19/CD20 Dual-CAR-T cells (CD19/CD20 Dual-CAR-T cells)

B-cell Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+3
Trials 2Status Active
CGTLimited DatastaleNational Cancer Institute (NCI)Phase 1

Anti-CD19 and anti-CD20 bicistronic CAR T- cells (Anti-CD19 and anti-CD20 bicistronic CAR T- cells)

Chronic Lymphocytic Leukemia; B-Cell Chronic Lymphocytic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleSumithira VasuPhase 1

Anti-CD19/CD20/CD22 CAR T-Cells (Anti-CD19/CD20/CD22 CAR T-Cells)

Recurrent Acute Lymphoblastic Leukemia; Recurrent B Acute Lymphoblastic Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleSouthwest Hospital, ChinaPhase 2

Anti-CD20-CAR-transduced T cells (Anti-CD20-CAR-transduced T cells)

Leukemia; Lymphoma · CD20

#CD20#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleBeijing BiotechPhase 2

Autologous CD19/CD20 dual-target CAR-T module (Autologous CD19/CD20 dual-target CAR-T module)

Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia; Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting
CGTLimited DatastaleSouthwest Hospital, ChinaPhase 2

CD19 or CD20 CAR T cells briging HSCT (CD19 or CD20 CAR T cells briging HSCT)

Lymphoma, Large B-Cell, Diffuse; Leukemia, Lymphocytic, Chronic, B-Cell · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+5
Trials 1Status Active
CGTLimited DatastaleiCell Gene TherapeuticsPhase 1

CD20-CD19 cCAR T cells (CD20-CD19 cCAR T cells)

B Cell Lymphoma; B Cell Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleChinese PLA General HospitalPhase 2

Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells (Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cells)

B Cell Leukemia; B Cell Lymphoma · CD19

#CD19#CGT#Phase2#cell-gene-therapy#CAR-T+4
Trials 1Status Active
CGTLimited DatastaleShanghai First Song Biotechnolo…Phase 1

anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells (anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells)

Relapsed/refractory Lymphoma; Relapsed/Refractory Leukemia · CD19

#CD19#CGT#Phase1#cell-gene-therapy#CAR-T+4
Trials 1Status Recruiting